Canopy Growth Corp’s (TSX:WEED) Big Move Into the U.S.: Why Investors Shouldn’t Get Too Excited

Canopy Growth Corp (TSX:WEED)(NYSE:CGC) is finally going to be able to penetrate the U.S. market, but not without some big limitations.

| More on:

Earlier this week, Canopy Growth Corp (TSX:WEED)(NYSE:CGC) was given a license to produce hemp in New York State. While it’s a big milestone for a TSX-listed cannabis stock, investors need to temper their expectations. There are, after all, some big limitations, and it’s not going to be able to compete at the same level other U.S. cannabis companies will be able to, especially if the state legalizes recreational use.

Investors will recall last year when the TSX reminded cannabis companies that running afoul of federal U.S. laws would mean a stock is not in compliance with listing requirements on the TSX. The announcement was in response to some Canadian companies having interests in the U.S. cannabis industry.

While it’s true that the U.S. recently passed the farm bill and will now permit hemp-derived cannabidiol (CBD), that’s all that it has legalized. CBD as a whole is not legal, nor is tetrahydrocannabinol (THC). The levels of THC have to be very minor, at no more than 0.3%, which won’t have much effect.

Canopy Growth and any TSX-based stock would have to ensure that they only sell cannabis products that have been legalized at the federal level. Even then, it’s still up to the individual states to decide to allow the products or not, so hemp products can’t automatically be sold everywhere.

Why TSX companies are still at a big disadvantage

The problem for Canopy Growth and others that look to expand into the U.S. is that local firms have big advantages today. A company like MedMen Enterprises Inc (CNSX:MMEN), for instance, has a presence in several U.S. states. If recreational marijuana becomes legal in New York, I’d expect it would jump all over that. And without the restrictions of the TSX, it wouldn’t be selling just hemp.

While hemp products will definitely appeal to medical marijuana users, that’s a very small subset of the industry. Without much more research being done on cannabis, many patients will hesitate to try it and so doctors will be hesitant to prescribe marijuana. It’s still a very big hurdle in the minds of many people, as not everyone is convinced that it can provide medicinal benefits. Until that happens, the medical market is going to take a long time to grow. It’s certainly a long-term play, but that shouldn’t excite investors.

While companies wait for the medical market to take off, MedMen and other unobstructed companies can be left to dominate the recreational market and establish a strong brand loyalty well before Canopy Growth is able to become a major player in the U.S. market.

Bottom line

While this is certainly good news for Canopy Growth, investors shouldn’t read too much into this. We’ve already seen how expectations in the industry can get more than a little out of whack, and the same could be happening all over again. Ultimately, until recreational marijuana is going to be legalized by the U.S. government, TSX-based stocks are going to remain at a significant disadvantage. The farm bill was a good start, but we’ve still got a long way to go.

Should you invest $1,000 in Brookfield Renewable Partners right now?

Before you buy stock in Brookfield Renewable Partners, consider this:

The Motley Fool Stock Advisor Canada analyst team just identified what they believe are the Top Stocks for 2025 and Beyond for investors to buy now… and Brookfield Renewable Partners wasn’t one of them. The Top Stocks that made the cut could potentially produce monster returns in the coming years.

Consider MercadoLibre, which we first recommended on January 8, 2014 ... if you invested $1,000 in the “eBay of Latin America” at the time of our recommendation, you’d have $21,345.77!*

Stock Advisor Canada provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month – one from Canada and one from the U.S. The Stock Advisor Canada service has outperformed the return of S&P/TSX Composite Index by 24 percentage points since 2013*.

See the Top Stocks * Returns as of 4/21/25

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor David Jagielski has no position in any of the stocks mentioned.

More on Investing

A red umbrella stands higher than a crowd of black umbrellas.
Dividend Stocks

The Top Canadian Stocks to Buy Immediately With $4,000

Insurance stocks are some of the strongest options, because we all need to pay it! And these three look top…

Read more »

dividends grow over time
Dividend Stocks

This Incredible Monthly Payer Is Down 17% and Looks Irresistible

Are you looking for an alternative source for a monthly paycheck? This stock is an irresistible deal to lock in…

Read more »

analyze data
Investing

This Canadian Stock Is Down 13% in a Month: It’s Still a Great Buy

Here's why the recent 13% slump in Barrick Gold (TSX:ABX) is one Canadian investors may want to consider buying to…

Read more »

investor looks at volatility chart
Tech Stocks

1 TSX Down 22% to Buy and Hold as Volatility Persists

Shopify stock has had its fair shares of ups and downs, but right now this rebounding tech stock looks like…

Read more »

top TSX stocks to buy
Dividend Stocks

This Monthly Income TSX Stock Paying 2.7% Looks Like a Bargain Today

Savaria is a TSX dividend stock that has crushed broader market returns over the past two decades. Is the Canadian…

Read more »

data analyze research
Dividend Stocks

This Canadian Blue-Chip Down 36% Is a Once-in-a-Decade Opportunity 

Rarely does an opportunity come to buy a blue-chip stock at a decade-low price. It helps you catch up on…

Read more »

Silver coins fall into a piggy bank.
Dividend Stocks

Here’s Why at 45, the Average Canadian TFSA and RRSP Isn’t Enough

Get it all with this energy stock that offers dividends now and major future growth.

Read more »

Caution, careful
Investing

The Truth About Canada’s Market Slump: 2 Warning Signs and 1 Massive Recovery Catalyst

Let's dive into the recent slump in the Canadian stock market and try to gauge where the TSX could be…

Read more »